NEW YORK (GenomeWeb News) – Fluidigm and Olink Bioscience today announced a co-marketing deal that combines each other's technologies to enable the interrogation of 96 samples across 92 proteins in one run from one microliter of sample in less than one day.
Under the terms of the deal, the firms will co-market Fluidigm's BioMark HD System with Olink's Proseek Multiplex technology, a technology combination that enables researchers to simultaneously analyze 96 human samples against a panel of 92 analytes, including growth factors, inflammatory markers, soluble receptors, and cancer antigens. By adding four control analytes, researchers will be able to obtain results for up to 9,216 reactions in a few hours, Fluidigm and Olink said.
Fluidigm said that its BioMark HD System produces high-quality data from RNA, miRNA, and DNA from sample sizes down to the single cell level. Its capabilities now include protein analysis. Olink's Proseek Multiplex is a multivariate protein biomarker detection kit that allows multiplexing of immunoassays. The technology is based on the firm's Proximity Extension Assay.
The first 92-plex Olink panel, the Proseek Multiplex Oncology I 96x96 Kit, is directed at biomarker discovery for cancer. Panels for cardiovascular disease and inflammation are planned for later this year.
"Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity when more and more assays are run simultaneously," Olink President and CEO Simon Fredriksson said in a statement. "Olink's Proseek Multiplex generates high-quality data even in highly multiplexed formats, and using these assays in conjunction with Fluidigm's BioMark HD System gives protein researchers easy access to unprecedented volume and quality of data."
Financial and other terms of the deal were not disclosed.